Company news

Certara, Inc. news in 2021

Certara, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions

December 20, 2021

Certara Announces Release of Pinnacle 21 Enterprise Software

December 12, 2021

Certara to Host Investor Day on December 15, 2021

December 7, 2021

Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

December 1, 2021

Certara Announces Update of D360™ Scientific Informatics Software

November 28, 2021

Certara Announces Closing of Public Offering of Common Stock

November 21, 2021

Certara Announces Pricing of Public Offering of Common Stock

November 16, 2021

Certara Announces Proposed Public Offering of Common Stock

November 14, 2021

Certara Reports Third Quarter 2021 Financial Results

November 8, 2021

Certara Appoints James E. Cashman III as Chairman of Board of Directors

November 7, 2021

Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

November 2, 2021

Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services

October 27, 2021

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

October 24, 2021

Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021

October 18, 2021

Certara Appoints Patrick F. Smith to President of Integrated Drug Development

October 11, 2021

Certara Appoints Drayton T. Virkler as Chief Commercial Officer

October 4, 2021

Certara Completes Acquisition of Pinnacle 21

October 3, 2021

Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process

September 29, 2021

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

September 21, 2021

Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation

September 19, 2021

Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 12, 2021

Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data

August 4, 2021

Certara Reports Second Quarter 2021 Financial Results

August 4, 2021

Certara’s Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19

July 22, 2021

Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members

July 14, 2021

Certara to Report Second Quarter 2021 Financial Results on August 5, 2021

July 13, 2021

Certara Announces New Chief Human Resources Officer

July 12, 2021

Certara Announces Update of BaseCase Software, the Company’s Value Communication Platform

July 7, 2021

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory Submissions

June 22, 2021

Certara Appoints Dr. Carol Gallagher as New Independent Board Member

June 13, 2021

Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

May 19, 2021

Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies

May 12, 2021

Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance

May 5, 2021

Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

May 3, 2021

Certara to Present at the BofA Securities 2021 Virtual Health Care Conference

April 29, 2021

Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021

April 21, 2021

Certara Set to Join Russell 1000® Index

March 10, 2021

Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance

March 3, 2021

Certara to Present at the Barclays Global Healthcare Conference

February 25, 2021

The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic Approvals

February 24, 2021

Certara to Report Fourth Quarter and Full Year 2020 Preliminary Financial Results on March 4, 2021

February 16, 2021

Certara Releases Simcyp™ PBPK Simulator Version 20, Including Newly Expanded Biologics Software

January 26, 2021

Calls in 2021

Decks in 2021